Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown to reduce bleeding events without increased cardiovascular events vs. standard DAPT, according to guidelines. However, the rate of major bleeding within the first month after procedure remains significant when using these strategies. The use of aspirin-free therapies (ASA)<a href="https://solaci.org/en/2023/08/29/esc-2023-stopdapt-3-2/" title="Read more" >...</a>
Approximately 1 million pacemakers (PM) or Implantable cardioverter-defibrillators (ICDs) are placed every year around the world, and it has been observed that 30% of these cases present left ventricular dysfunction, mainly systolic. This dysfunction is attributed to PM induced right ventricle dyssynchrony, which in time leads to hospitalization for cardiac failure and increased clinical adverse<a href="https://solaci.org/en/2023/08/29/esc-2023-budapest-crt-upgrade-trial-2/" title="Read more" >...</a>
Dual antiplatelet therapy (DAPT) is the current standard for preventing thrombotic events in high-risk patients with coronary artery disease, as well as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). However, this approach increases the risk of bleeding. To reduce this risk, there have been studies that discontinued the use of<a href="https://solaci.org/en/2023/08/29/mact-study-monotherapy-with-p2y12-inhibitor-associated-with-colchicine-after-acute-coronary-syndrome/" title="Read more" >...</a>
The introduction of drug coated balloons (DCB) has become an innovative therapeutic alternative to current treatments. Paclitaxel-coated balloons (PCB) have been used to treat in-stent restenosis (ISR) and also approach CAD in native arteries. More recently, sirolimus-coated balloons (SCB) are being looked at as part of pilot studies and smaller registries with preliminary results. The<a href="https://solaci.org/en/2023/08/23/eastbourne-registry-use-of-sirolimus-coated-balloons-in-coronary-artery-disease/" title="Read more" >...</a>
Transcatheter aortic valve replacement (TAVR) has shown remarkable benefits and continues to advance towards lower-risk patients and younger ages. However, one of its limitations lies in the demand for a permanent pacemaker (PPM), which during TAVR early stages with self-expanding valves reached 30%. Uncertainty persists regarding the evolution of patients undergoing PPM implantation after TAVR,<a href="https://solaci.org/en/2023/08/17/predictors-and-evolution-of-permanent-pacemaker-after-tavr-with-self-expanding-valves/" title="Read more" >...</a>
The use of intravascular ultrasound (IVUS) to guide percutaneous coronary interventions (PCI) has been shown to reduce the risk of major adverse cardiovascular events (MACE) across controlled randomized studies, registries and meta-analysis. Current guidelines recommend the use of IVUS in left main disease and complex lesions. As the prevalence of complex PCI increases over time,<a href="https://solaci.org/en/2023/08/16/long-term-outcomes-after-complex-pci-according-to-operator-experience-and-use-of-ivus/" title="Read more" >...</a>
The area of records within SOLACI – SOLACI Research – continues to grow and share the results of its investigations with the entire Latin American interventional community. In this case, a dedicated session was held during the SOLACI-SBHCI 2023 Congress to present the data from the SOLACI records and to discuss the challenges of carrying<a href="https://solaci.org/en/2023/08/04/solaci-research-registries-were-presented-at-the-solaci-sbhci-2023-congress/" title="Read more" >...</a>
The proportion of patients undergoing high risk PCI (HRPCI) is on the rise. It includes patients with different clinical, anatomical and procedural characteristics, such as low ejection fraction, severe vascular disease, three vessel or left main disease, severe lesion calcification and the use of atherectomy. Mechanical circulatory support devices (MCS) during HRPCI, such as the<a href="https://solaci.org/en/2023/07/26/are-there-sex-differences-in-plvad-assisted-high-risk-pci/" title="Read more" >...</a>
Chronic total occlusions (CTOs) account for approximately 15-20% of patients with stable coronary artery disease. This field has seen various advances regarding treatment, leading to an improvement in the success rate of procedures. According to registries and randomized studies, the main indication for percutaneous coronary intervention (PCI) of CTO should be based more on clinical<a href="https://solaci.org/en/2023/07/24/eurocto-safety-and-benefit-at-3-years/" title="Read more" >...</a>
Endovascular treatment of lesions in femoropopliteal territory (FPA) has become the main therapeutic option, seeing as it is less invasive and has faster recovery. It has used different devices, such as conventional bare metal stents (BMS), balloon angioplasty (POBA), and drug coated balloons (DCB), as well as drug eluting stents (DES). However, real world data<a href="https://solaci.org/en/2023/07/24/device-effectiveness-for-femoropopliteal-artery-disease-treatment-analysis-of-k-vis-ella-registry/" title="Read more" >...</a>